Resources 
    • About Us 

    • Home Report Store In-vitro Diagnostics Market
    In-vitro Diagnostics Market

    In Vitro Diagnostics (IVD) Market Size, Share, Forecast, & Trends Analysis by Offering (Kits) Technology (Immunoassay, Molecular Diagnostics [PCR, NGS] Rapid Test) Application (Infectious Diseases, Oncology) Diagnostic Approach (Lab, POC) - Global Forecast to 2031

    Report ID:MRHC - 104132 Pages: 525 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 Hours

    The In Vitro Diagnostics (IVD) Market was valued at $77 billion in 2023. This market is expected to reach $116.3 billion by 2031 from an estimated $80.9 billion in 2024, at a CAGR of 5.3% during the forecast period from 2024 to 2031.

    IVD Market Size & Forecast

    The growth of the In Vitro Diagnostics (IVD) market is driven by the rising prevalence of chronic diseases, the increasing occurrence of infectious diseases, increasing awareness of the importance of early disease diagnosis, the growing demand for point-of-care (POC) diagnostic & rapid diagnostic solutions, rising healthcare expenditures, and increasing investments in research and development. However, stringent technical requirements and regulatory processes for high/moderate-complexity tests, and variance in test results observed in rapid IVD tests restrain the growth of the market. Moreover, emerging economies, an inclination toward personalized medicine, and advancements in genomics & proteomics are expected to offer significant growth opportunities for market stakeholders. The evolving regulatory landscape poses a challenge to the growth of the market.

    IVD Market Growth Drivers

    Rising Prevalence of Chronic Diseases and Increasing Geriatric Population

    The global incidence of chronic diseases and conditions, including cancer, diabetes, arthritis, and cardiovascular diseases, is escalating. The World Health Organization reports that chronic diseases are responsible for 41 million deaths annually, representing approximately 74% of global mortality. Contributing factors to this upward trend include an aging population and social behaviors such as tobacco and alcohol consumption, physical inactivity, and poor dietary habits. The International Diabetes Federation projects that the global prevalence of diabetes will increase to 11.3% of the population by 2030, up from 10.5% in 2021.

    The majority of older adults are diagnosed with chronic diseases due to declining bodily functions and weakened immunity. According to the World Population Prospects, the population aged 65 and older is expanding at a faster rate than other age groups. In 2019, there were 703 million individuals in this age group globally, with projections indicating this number will double to 1.5 billion by 2050. Consequently, the increasing prevalence of chronic diseases, combined with the growing geriatric population, is expected to drive an increase in diagnostic testing and subsequently boost growth in the IVD market.

    In Vitro Diagnostics (IVD) MarketClick here to: Get Free Sample Pages of this Report

    Rising Awareness Regarding Early Disease Diagnosis

    Early diagnosis of infectious diseases facilitates improved treatment and future care. It enables healthcare professionals and patients to make crucial medical decisions regarding care and support. Growing awareness of the benefits of early disease diagnosis underscores its importance. Detecting a disease in its early stages can lead to substantial cost savings in treatment. For example, the World Health Organization reports that, in certain high-income countries, early diagnosis of cancer can reduce treatment costs by two to four times. In addition, early diagnosis is often lifesaving for patients with critical conditions such as cancer.

    Furthermore, key players and organizations in the IVD market are actively pursuing initiatives to enhance early diagnosis and reduce mortality rates associated with infectious diseases. For example, in June 2022, Illumina, Inc. (U.S.) and Ochsner Health System (U.S.) introduced new initiatives by providing multi-cancer early detection tests to patients at risk of cancer. Consequently, the increasing awareness of early disease diagnosis, combined with supportive initiatives, is anticipated to drive growth in the market.

    IVD Market Trends

    Increasing Applications of Next-generation Sequencing Technology

    NGS (Next-Generation Sequencing) technology has transformed genetic disease diagnostics through its rapid, high-throughput, and cost-effective capabilities. NGS can concurrently analyze hundreds of genes, the entire exome, and even the whole genome, providing researchers with profound insights into the genetic diversity of rare diseases. It also facilitates the study of unknown species and complex conditions. Recently, NGS technology has gained significant traction in diagnosing infectious diseases, immunological disorders, and hereditary conditions. Additionally, it is extensively utilized for noninvasive prenatal diagnostics and for making therapeutic decisions in somatic cancers.

    NGS testing is becoming increasingly integral to companion diagnostics. As cancer prevalence rises, precision or personalized medicine is gaining prominence in oncology, making the development of effective therapies a crucial focus for researchers. Moreover, ongoing technological advancements are anticipated to drive the creation of faster, more accurate, and portable NGS systems, thereby broadening their applications across medical, agricultural, ecological, and other domains. Improvements in sample preparation, liquid handling, bioinformatics, robotics, and miniaturization are expected to facilitate these advancements.

    Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests

    The demand for high-quality medical services is continuously increasing. Technological innovations, such as portable devices designed for home use or in remote and resource-limited environments, significantly enhance both the quantity and quality of medical care. Smartphone-based platforms are being utilized in various fields, including tele-imaging, food technology, and education, demonstrating their versatility and broad range of medical applications. Rapid diagnostics are crucial for effective patient screening across healthcare settings. Given the high costs of traditional diagnostic methods and the limited availability of benchtop readers in remote areas, the demand for smartphone-based rapid diagnostics is growing. Many companies in the rapid diagnostics market are developing or have already developed smartphone-based, end-to-end platforms that integrate with mobile applications to provide test results efficiently in point-of-care settings.

    Smartphone-based detection methods offer automated result detection and analysis, complementing human expertise. Patient data transactions are secured using blockchain technology to ensure privacy and integrity. Companies are actively engaged in developing and launching smartphone-based platforms. For example, in August 2021, Becton, Dickinson, and Company (U.S.) received FDA Emergency Use Authorization (EUA) for the BD Veritor At-Home COVID-19 Test. This rapid antigen test utilizes the Scanwell Health Mobile App to interpret and provide reliable results within 15 minutes.

    IVD Market Opportunity

    Emerging Economies

    Countries like India, Malaysia, Bangladesh, China, South Korea, Argentina, and Brazil are recognized as emerging economies due to their expanding GDPs and high rates of new technology adoption. These emerging economies are driving the demand for healthcare services and treatments, fueled by factors such as rapid urbanization, advancements in healthcare infrastructure, increased healthcare expenditures, broader healthcare insurance coverage, rising disposable incomes, and the growing prevalence of both non-communicable and infectious diseases.

    Increasing urbanization and rising GDP per capita in emerging economies are driving the demand for healthcare services and treatments. Urbanization often results in higher wages, enhanced quality of life, and improved access to healthcare services. Consequently, as urbanization progresses in these economies, it is anticipated to stimulate the development of healthcare systems, leading to the expansion of hospitals, clinics, and diagnostic laboratories. This expansion will improve access to healthcare services and create lucrative opportunities for companies operating in the IVD market.

    IVD Market Study: Key Findings

    The Reagents & Kits Segment to Account for the Largest Share of this Market in 2024

    Based on offering, the IVD market is segmented into reagents and kits, systems, and software & services. In 2024, the kits & reagents segment is expected to account for the largest share of 81.1% of the IVD market. The substantial market share of this segment is due to the frequent use of reagents and kits for detecting a variety of chronic diseases, as well as the wide availability of a diverse range of reagents and consumables for diagnosing different conditions.

    Furthermore, the kits and reagents segment is slated to register the highest CAGR of 5.0% during the forecast period. The increased volume of testing for infectious diseases and the rising awareness among the general population about self-testing kits drive this segment's growth.

    The Molecular Diagnostics Segment to Account for the Largest Share of this Market in 2024

    Based on technology, the IVD market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, point-of-care (POC) diagnostics, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies. In 2024, the molecular diagnostics segment is expected to account for the largest share of 23.1% of the IVD market. The large market share is due to the growing prevalence of infectious diseases and the superior sensitivity of molecular diagnostics for detecting infectious agents.

    Moreover, the molecular diagnostics segment is expected to record the highest CAGR during the forecast period. The high sensitivity of various technologies, low sample volume requirements, and cost-effectiveness drive this segment's growth.

    The Infectious Diseases Segment to Account for the Largest Share of this Market in 2024

    Based on application, the IVD market is segmented into infectious diseases, oncology, diabetes, cardiology, nephrology, autoimmune disorders, and other applications. In 2024, the infectious diseases segment is expected to account for the largest share of 37.8% of IVD market. The large market share of this segment is attributed to the increasing prevalence of infectious diseases, government initiatives to promote awareness and testing, and global outbreaks of infectious diseases.

    However, the cardiology segment is anticipated to record the highest CAGR during the forecast period. This segment's growth is driven by the increasing incidence of cancer and the rising number of diagnostic laboratories.

    The Lab Testing Segment to Account for the Largest Share of this Market in 2024

    Based on diagnostic approach, the IVD market is segmented into laboratory testing, OTC/self-testing, and point-of-care testing. In 2024, the laboratory testing segment is expected to account for the largest share of the IVD market. This segment’s large market share is attributed to the higher accuracy & reliability of lab testing compared to point-of-care testing, low costs, the availability of a wide range of IVD tests, and the presence of robust quality assurance programs.

    However, the point-of-care testing segment is projected to record the highest CAGR during the forecast period. This segment's growth is driven by quick results, the ability to be performed by non-healthcare professionals, shorter hospital stays, easy sample collection, and rapid medical decisions.

    The Hospitals & Clinics Segment to Account for the Largest Share of this Market in 2024

    Based on end user, the IVD market is segmented into diagnostic laboratories, hospitals & clinics, home healthcare, and other end users, which includes nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories. In 2024, the hospitals & clinics segment is expected to account for the largest share of the IVD  market. This segment's substantial market share is due to hospitals and clinics being the primary contact points for patients with health conditions, the expansion of diagnostic capabilities during the COVID-19 pandemic, and the significant global burden of chronic diseases.

    Moreover, the hospitals & clinics segment is projected to record the highest CAGR during the forecast period. This segment's growth is driven by the increasing number of tests, government funding, the increasing hospitalization rate, and the increasing demand for diagnostic products.

    Geographical Analysis

    In 2024, North America is expected to account for the largest share of 37.5% of the IVD market. The key factors contributing to the large share of this regional market include the rising prevalence of chronic and infectious diseases, increased awareness about early disease diagnosis, growing adoption of advanced diagnostic products, and heightened funding activities combined with novel advancements in diagnostic technologies.

    However, Asia-Pacific is poised to record the highest CAGR during the forecast period. This segment's growth is driven by continuous improvements in healthcare infrastructure, the rising number of hospitals, increasing governments in this sector, rapid urbanization, the growing burden of infectious diseases, and efforts to improve the accessibility of diagnostic services to enhance the prevention of infectious diseases by developing diagnostic products or platforms.

    IVD Market: Key Companies

    The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants over the past three to four years. The key players profiled in the IVD market report are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), Ortho-Clinical Diagnostics, Inc. (U.S.), Agilent Technologies Inc. (U.S.), DiaSorin S.p.A. (Italy), Hologic, Inc. (U.S.), Abcam Plc (U.K.), Raybiotech, Inc. (U.S.), Oy Medix Biochemica Ab (Finalnd), InBios International, Inc. (U.S.), Dextra Laboratories Ltd. (U.K.), Genecopoeia, Inc. (U.S.), Sakura Finetek USA, Inc. (U.S.), and Edvotek, Inc. (U.S.).

    IVD Market Industry Overview: Latest Developments from Key Industry Players

    •  In January 2023, Becton, Dickinson, and Company (U.S.) and CerTest Biotec (Spain) received Emergency Use Authorization (EUA) from the US FDA for their molecular polymerase chain reaction (PCR) assay, VIASURE Monkeypox Virus Real-Time PCR Reagent.
    • In January 2023, Beckman Coulter Inc. (U.S.), a subsidiary of Danaher Corporation (U.S.), partnered with MeMed Diagnostics Ltd (Israel) to commercialize and develop the MeMed BV test. This test, which differentiates between viral and bacterial infections, is intended for use with Immunoassay Analyzers.
    • In September 2022, Becton, Dickinson and Company (U.S.) launched its cloud-based software solution, BD Research Cloud. This platform is designed to streamline and enhance the workflow of flow cytometry, enabling faster and higher-quality experiments.

    IVD Market Research Summary

    Particulars

    Details

    Page No

    525

    Format

    PDF

    Forecast Period

    2024-2031

    Base Year

    2023

    CAGR

    5.3%

    Market Size (Value)

    $116.3 billion by 2031

    Segments Covered

    By Offering

    • Reagents & Kits
    • Instruments
    • Software & Services

    By Technology

    • Molecular Diagnostics
      • Polymerase Chain Reaction (PCR)
      • Hybridization
      • Isothermal Nucleic Acid Amplification Technology
      • DNA Sequencing & Next-Generation Sequencing
      • Microarrays
      • Mass Spectrometry
      • Other Molecular Diagnostic Technologies
        (Note:-Other Molecular Diagnostic Technologies majorly include electrophoresis, Ligase Chain Reaction (LCR), Northern Blot, and Southern Blot)
    • Point of Care (POC) Diagnostics
      • Lateral Flow Assays/Rapid Tests
      • POC Molecular Diagnostics
      • Other PoC Products
    • Immunoassay/Immunochemistry
      • Enzyme-linked Immunosorbent Assays (ELISA)
      • Enzyme-linked Immunospot Assays (ELISPOT)
      • Western Blotting
      • Radioimmunoassay
    • Biochemistry/Clinical Chemistry
      • Metabolic Panel
      • Electrolyte Panel
      • Liver Panel
      • Lipid Profile
      • Renal Profile
      • Thyroid Function Panel
    • Whole Blood Glucose Monitoring
    • Microbiology
    • Hematology
    • Coagulation/Hemostasis
    • Urinalysis
    • Other IVD Technologies
      (Note:Other IVD technologies comprise anatomical pathology, histochemistry, and loop-mediated amplification).

    By Application

    • Infectious Diseases
      • Sexually Transmitted Diseases (STD) Testing
      • Healthcare-associated Infections (HAIs)
      • Hepatitis
      • HIV
      • Tropical Diseases
      • Respiratory Infections (Excluding Influenza)
      • Influenza
      • Other Infectious Diseases
    • Oncology
    • Diabetes
    • Cardiology
    • Nephrology
    • Autoimmune Disorders
    • Other Applications
      (Note 1:Other applications comprise drugs of abuse tests, coagulation tests, neonatal testing, genetic testing, and neurological disorders testing.
      Note 2:Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).

    By Diagnostic Approach

    • Laboratory Testing 
    • OTC/Self-testing
    • Point-of-Care Testing

    By End User

    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Home Healthcare
    • Other End Users
      (Note: Other end users comprise nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories.)

    Countries Covered

    North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), the Middle East (Saudi Arabia & Rest of Middle East), and Africa (South Africa and Rest of Africa)

    Key Companies

    Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), Ortho-Clinical Diagnostics, Inc. (U.S.), Agilent Technologies Inc. (U.S.), DiaSorin S.p.A. (Italy), Hologic, Inc. (U.S.), Abcam Plc (U.K.), Raybiotech, Inc. (U.S.), Oy Medix Biochemica Ab (Finalnd), InBios International, Inc. (U.S.), Dextra Laboratories Ltd. (U.K.), Genecopoeia, Inc. (U.S.), Sakura Finetek USA, Inc. (U.S.), and Edvotek, Inc. (U.S.)

    Key questions answered in the IVD market report:

    This study provides insights into the IVD market segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (molecular diagnostics, point of care (POC), immunoassay/immunochemistry, biochemistry/clinical chemistry, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. This report involves the value analysis of various segments and sub-segments of the IVD market at the regional and country levels.

    The IVD market is projected to reach $116.3 billion by 2031, at a CAGR of 5.3% during the forecast period.

    The reagents and kits segment is expected to account for the largest share of the global IVD market in 2024. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis support this segment's largest share.

    Based on the technology, the molecular diagnostics segment is projected to create more traction.

    Based on application, the cardiology segment is projected to register the highest growth during the forecast period due to the growing cardiovascular disease (CVD) burden and increasing research on cardiac biomarkers.

    Based on end-user, the hospitals and clinics segment is projected to register the highest growth during the forecast period due to the high number of hospitalizations due to various diseases, the rising geriatric population, increasing healthcare access and expenditure, and the rising prevalence of healthcare-associated Infections (HAIs).

    The rising prevalence of chronic and infectious diseases, growing awareness for early disease diagnosis, a shift in the focus from centralized to point-of-care testing, and technological innovations are factors supporting the growth of this market. Further, emerging economies, the emergence of the COVID-19 pandemic, and advances in genomics and proteomics are anticipated to offer significant growth opportunities for companies operating in this market.

    The key players operating in the global IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), Ortho-Clinical Diagnostics, Inc. (U.S.), Agilent Technologies Inc. (U.S.), DiaSorin S.p.A. (Italy), Hologic, Inc. (U.S.), Abcam Plc (U.K.), Raybiotech, Inc. (U.S.), Oy Medix Biochemica Ab (Finalnd), InBios International, Inc. (U.S.), Dextra Laboratories Ltd. (U.K.), Genecopoeia, Inc. (U.S.), Sakura Finetek USA, Inc. (U.S.), and Edvotek, Inc. (U.S.).

    Emerging countries from Asia and Latin America are projected to offer significant growth opportunities for vendors in this market due to rapid urbanization, increasing investments by healthcare providers in infrastructure improvement, growing infectious diseases, and growing accessibility to healthcare services and advanced products.

    Enquire
    Check Discount
    Related Tag: In-vitro Diagnostics Market IVD Market Disease Diagnostics Diagnostic Assays Diagnostic Kits Rapid Diagnostics Diagnostic Immunoassays Molecular Diagnostics
    In Vitro Diagnostics
    Healthcare

    1.   Overview
       1.1.   Market Definition & Scope
       1.2.   Market Ecosystem
       1.3.   Currency and Limitations
       1.4.   Key Stakeholders
    2.   Research Methodology
       2.1.   Research Approach
       2.2.   Process of Data Collection & Validation
          2.2.1.   Secondary Research
          2.2.2.   Primary Research/Interviews with Key Opinion Leaders from the Industry
       2.3.   Market Sizing and Forecast
          2.3.1.   Market Size Estimation Approach
          2.3.2.   Growth Forecast Approach
          2.3.3.   Market Share Analysis
       2.4.   Assumptions For the Study
    3.   Executive Summary
    4.   Market Insights
       4.1.   Market Overview 
       4.2.   Drivers 
          4.2.1.   Rising Prevalence of Chronic Diseases Coupled with Increasing Geriatric Population
          4.2.2.   Increasing Incidence of Infectious Diseases
          4.2.3.   Growing Demand for Point-of-Care (POC) and Rapid Diagnostics 
          4.2.4.   Rising Awareness Regarding Early Disease Diagnosis
          4.2.5.   Growing Healthcare Expenditure
          4.2.6.   Increasing Funding for Research Activities
       4.3.   Restraints
          4.3.1.   Stringent Technical Requirements and Regulatory Processes for High/Moderate-complexity Tests
          4.3.2.   Variance in Test Results Observed in Rapid IVD Tests
       4.4.   Opportunities
          4.4.1.   Emerging Economies
          4.4.2.   Inclination Toward Personalized Medicine
          4.4.3.   Advancements in Genomics and Proteomics
       4.5.   Challenges 
          4.5.1.   Evolving Regulatory Landscape
       4.6.   Technology Trends
          4.6.1.   Integration of Artificial Intelligence & Machine Learning in Molecular Diagnostics
          4.6.2.   Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests
          4.6.3.   Increasing Applications of Next-generation Sequencing Technology
       4.7.   Macroindicators
          4.7.1.   Prevalence of Infectious and Chronic Diseases
          4.7.2.   Number of HIV Cases 
          4.7.3.   Number of New Cancer Cases 
          4.7.4.   Healthcare Expenditure as a Percentage of GDP, by Country
          4.7.5.   Biopharmaceutical R&D Expenditure
          4.7.6.   Percentage of Urban Population in Emerging Countries 
       4.8.   Regulatory Analysis
          4.8.1.   North America
             4.8.1.1.   U.S.
             4.8.1.2.   Canada
          4.8.2.   Europe
          4.8.3.   Asia-Pacific
             4.8.3.1.   China
             4.8.3.2.   Japan
             4.8.3.3.   India
          4.8.4.   Latin America
          4.8.5.   Middle East
       4.9.   Value Chain Analysis
       4.10.   Technology Evolution/Market Evolution
       4.11.   Patent Analysis
       4.12.   Porter’s Five Forces Analysis
       4.13.   PESTLE Analysis
       4.14.   Consumer Behavior Analysis
          4.14.1.   Vendor Selection Criteria
          4.14.2.   Unmet Needs
          4.14.3.   Vendor/Brand Analysis
          4.14.4.   Product/Technology Adoption Trends
    5.   In Vitro Diagnostics (IVD) Market Assessment—by Offering
       5.1.   Overview
       5.2.   Reagents & Kits
       5.3.   Systems
       5.4.   Software & Services
    6.   In Vitro Diagnostics (IVD) Market Assessment—by Technology
       6.1.   Overview
       6.2.   Molecular Diagnostics
          6.2.1.   Polymerase Chain Reaction (PCR)
          6.2.2.   Hybridization
          6.2.3.   Isothermal Nucleic Acid Amplification Technology
          6.2.4.   DNA Sequencing & Next-generation Sequencing
          6.2.5.   Microarray
          6.2.6.   Mass Spectrometry
          6.2.7.   Other Molecular Diagnostic Technologies
       6.3.   Point-of-Care (POC) Diagnostics    
          6.3.1.   Lateral Flow Assays/Rapid Tests
          6.3.2.   POC Molecular Diagnostics
          6.3.3.   Other PoC Products
       6.4.   Immunoassay/Immunochemistry    
          6.4.1.   Enzyme-linked Immunosorbent Assays (ELISA)
          6.4.2.   Enzyme-linked Immunospot Assays
          6.4.3.   Western Blotting
          6.4.4.   Radioimmunoassay
       6.5.   Biochemistry/Clinical Chemistry    
          6.5.1.   Metabolic Panels
          6.5.2.   Electrolyte Panels
          6.5.3.   Liver Panels
          6.5.4.   Lipid Profiles
          6.5.5.   Renal Profiles
          6.5.6.   Thyroid Function Panels    
       6.6.   Whole Blood Glucose Monitoring
       6.7.   Microbiology    
       6.8.   Hematology    
       6.9.   Coagulation/Hemostasis    
       6.10.   Urinalysis    
       6.11.   Other IVD Technologies
    7.   In Vitro Diagnostics (IVD) Market Assessment—by Application
       7.1.   Overview    
       7.2.   Infectious Diseases    
          7.2.1.   Sexually Transmitted Diseases (STD) Testing
          7.2.2.   Healthcare-associated Infections (HAIs)
          7.2.3.   Hepatitis    
          7.2.4.   HIV
          7.2.5.   Tropical Diseases
          7.2.6.   Influenza
          7.2.7.   Respiratory Infections (Excluding Influenza)
          7.2.8.   Other Infectious Diseases
       7.3.   Oncology 
       7.4.   Diabetes 
       7.5.   Cardiology 
       7.6.   Nephrology
       7.7.   Autoimmune Disorders
       7.8.   Other Applications
    8.   In Vitro Diagnostics (IVD) Market Assessment—by Diagnostic Approach
       8.1.   Overview    
       8.2.   Lab Testing     
       8.3.   OTC/Self Testing    
       8.4.   Point-of-Care Testing    
    9.   In Vitro Diagnostics (IVD) Market Assessment—by End User
       9.1.   Overview    
       9.2.   Diagnostic Laboratories
       9.3.   Hospitals & Clinics    
       9.4.   Home Healthcare    
       9.5.   Other End Users    
    10.   In Vitro Diagnostics (IVD) Market Assessment—by Geography
        10.1.   Overview
        10.2.   North America
           10.2.1.   U.S.
           10.2.2.   Canada
        10.3.   Europe    
           10.3.1.   Germany
           10.3.2.   France
           10.3.3.   U.K.
           10.3.4.   Italy 
           10.3.5.   Spain
           10.3.6.   Switzerland
           10.3.7.   Rest of Europe
        10.4.   Asia Pacific
           10.4.1.   Japan
           10.4.2.   China
           10.4.3.   India
           10.4.4.   Australia
           10.4.5.   South Korea
           10.4.6.   Rest of Asia Pacific
        10.5.   Latin America    
           10.5.1.   Brazil
           10.5.2.   Mexico
           10.5.3.   Argentina
           10.5.4.   Rest of Latin America
        10.6.   Middle East    
           10.6.1.   Saudi Arabia
           10.6.2.   Rest of Middle East
        10.7.   Africa    
           10.7.1.   South Africa
           10.7.2.   Rest of Africa
    11.   Competition Analysis
        11.1.   Overview
        11.2.   Key Growth Strategies
        11.3.   Competitive Dashboard
           11.3.1.   Industry Leaders
           11.3.2.   Market Differentiators
           11.3.3.   Vanguards
           11.3.4.   Emerging Companies
        11.4.   Competitive Benchmarking
        11.5.   List of Key Distributors
        11.6.   Product Pipeline Analysis
        11.7.   Market Share Analysis, By Company (2023)
           11.7.1.   F.   Hoffmann-La Roche Ltd.
           11.7.2.   Abbott Laboratories
           11.7.3.   Danaher Corporation
           11.7.4.   Siemens Healthineers AG
           11.7.5.   Thermo Fisher Scientific Inc.    
    12.   Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
        12.1.   Abbott Laboratories
        12.2.   Agilent Technologies, Inc.
        12.3.   Becton, Dickinson and Company
        12.4.   bioMérieux SA
        12.5.   Bio-Rad Laboratories, Inc.
        12.6.   Danaher Corporation
        12.7.   DiaSorin S.p.A.
        12.8.   F.   Hoffmann-La Roche Ltd.   
        12.9.   Illumina, Inc.
        12.10.   QuidelOrtho Corporation
        12.11.   QIAGEN N.V.
        12.12.   Shenzhen Mindray Bio-Medical Electronics Co., Ltd
        12.13.   Siemens Healthineers AG 
        12.14.   Thermo Fisher Scientific Inc.   
        12.15.   Wama Diagnostica 
        12.16.   Wiener Laboratorios SAIC
        12.17.   Hologic, Inc.
        12.18.   Abcam Plc.
        12.19.   Raybiotech, Inc.
        12.20.   Oy Medix Biochemica Ab
        12.21.   InBios International, Inc.
        12.22.   Dextra Laboratories Ltd.
        12.23.   GeneCopoeia, Inc.
        12.24.   Sakura Finetek USA, Inc.
        12.25.   Edvotek, Inc.
                     (Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
    13.   Appendix
        13.1.   Available Customization
        13.2.   Related Reports

    List of Tables
    Table 1    Number of People with Diabetes Aged 20–79, by Region, 2021 Vs. 2030 Vs. 2045 (Thousand)
    Table 2    Population Aged 65 Years or Above, by Region, 2019 Vs. 2030 Vs. 2050 (Million)
    Table 3    Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
    Table 4    HIV Statistics (2021)
    Table 5    Healthcare Expenditure as a Percentage of GDP, by Country (2014 Vs. 2019)
    Table 6    Healthcare Expenditure, by Country (2020–2022)
    Table 7    Requirements For CLIA-Waived and Moderate/High-complexity POC Molecular Diagnostic Tests
    Table 8    Emerging Countries: Percentage of Urban Population (2021 Vs. 2025 Vs. 2050)
    Table 9    Biomarkers and Corresponding Targeted Therapies Currently Available
    Table 10    Clinical Applications of Genomics and Proteomics in Infectious Disease Diagnosis
    Table 11    Regulatory Authorities Governing In Vitro Diagnostics, by Country
    Table 12    Prevalence of Infectious and Chronic Diseases
    Table 13    HIV Statistics
    Table 14    Estimated Number of New Cancer Cases (2020 Vs. 2030)
    Table 15    Healthcare Expenditures as a Percentage of GDP, by Country
    Table 16    Biopharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
    Table 17    Percentage of Urban Population in Emerging Countries (2021 Vs. 2025 Vs. 2050)
    Table 18    Some of The Emergency Use Authorizations (EUAs) Granted for IVD During the COVID-19 Pandemic
    Table 19    Global In Vitro Diagnostics (IVD) Market, by Offering, 2022–2031 (USD Million)
    Table 20    Global IVD Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
    Table 21    Global IVD Systems Market, by Country/Region, 2022–2031 (USD Million)
    Table 22    Global IVD Software & Services Market, by Country/Region, 2022–2031 (USD Million)
    Table 23    Global In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 24    Global Molecular Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 25    Global Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 26    Key Companies Offering PCR Products
    Table 27    Global Polymerase Chain Reaction Market, by Country/Region, 2022–2031 (USD Million)
    Table 28    Global Hybridization Market, by Country/Region, 2022–2031 (USD Million)
    Table 29    Key Companies Offering Isothermal Nucleic Acid Amplification Products
    Table 30    Global Isothermal Nucleic Acid Amplification Market, by Country/Region, 2022–2031 (USD Million)
    Table 31    Key Companies Offering DNA Sequencing & Next-Generation Sequencing Products
    Table 32    Global DNA Sequencing and Next-Generation Sequencing Market, by Country/Region, 2022–2031 (USD Million)
    Table 33    Key Companies Offering Microarray Products
    Table 34    Global Microarrays Market, by Country/Region, 2022–2031 (USD Million)
    Table 35    Global Mass Spectrometry Market, by Country/Region, 2022–2031 (USD Million)
    Table 36    Other Molecular Diagnostic Technologies Market, by Country/Region, 2022–2031 (USD Million)
    Table 37    Global Point-of-Care (POC) Diagnostics Market, by Technology, 2022–2031, (USD Million)
    Table 38    Global Point-of-Care (POC) Diagnostics Market, by Country/Region, 2022–2031, (USD Million)
    Table 39    Global Lateral Flow Assays/Rapid Tests Market, by 2022–2031 (USD Million)
    Table 40    Global POC Molecular Diagnostics Market, 2022–2031 (USD Million)
    Table 41    Other POC Products Market, by Country/Region, 2022–2031 (USD Million)
    Table 42    Global Immunoassay/Immunochemistry Market, by Type, 2022–2031 (USD Million)
    Table 43    Global Immunoassay/Immunochemistry Market, by Country/Region, 2022–2031 (USD Million)
    Table 44    Global Enzyme-linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2022–2031 (USD Million)
    Table 45    EliSpot Vs. Conventional ELISA
    Table 46    Global Enzyme-linked ImmunoSpot Assays (Elispot) Market, by Country/Region, 2022–2031 (USD Million)
    Table 47    Global Western Blotting Market, by Country/Region, 2022–2031 (USD Million)
    Table 48    Global Radioimmunoassay Market, by Country/Region, 2022–2031 (USD Million)
    Table 49    Global Biochemistry/Clinical Chemistry Market, by Type, 2022–2031 (USD Million)
    Table 50    Global Metabolic Panels Market, by Country/Region, 2022–2031 (USD Million)
    Table 51    Global Electrolyte Panels Market, by Country/Region, 2022–2031, (USD Million)
    Table 52    Global Liver Panels Market, by Country/Region, 2022–2031, (USD Million)
    Table 53    Global Lipid Profiles Market, by Country/Region, 2022–2031 (USD Million)
    Table 54    Global Renal Profiles Market, by Country/Region, 2022–2031 (USD Million)
    Table 55    Global Thyroid Function Panels Market, by Country/Region, 2022–2031 (USD Million)
    Table 56    Number of People with Diabetes Aged 20–79 Years, by Region, 2019 Vs. 2030 Vs. 2045 (In Million)
    Table 57    Global Whole Blood Glucose Monitoring Market, by Country/Region, 2022–2031 (USD Million)
    Table 58    Key Companies Offering Microbiology-based IVD Products
    Table 59    Global Microbiology Market, by Country/Region, 2022–2031 (USD Million)
    Table 60    Key Companies Offering Hematology Products
    Table 61    Global Hematology Market, by Country/Region, 2022–2031 (USD Million)
    Table 62    Key Companies Offering Coagulation and Hemostasis Products
    Table 63    Global Coagulation and Hemostasis Market, by Country/Region, 2022–2031 (USD Million)
    Table 64    Key Companies Offering Urinalysis Products
    Table 65    Global Urinalysis Market, by Country/Region, 2022–2031 (USD Million)
    Table 66    Global Other IVD Technologies Market, by Country/Region, 2022–2031 (USD Million)
    Table 67    Global In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 68    Global In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 69    Global In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
    Table 70    Recently Launched and Approved Rapid Diagnostic Tests for COVID-19 Detection
    Table 71    Global In Vitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2022–2031 (USD Million)
    Table 72    Global In Vitro Diagnostics Market for Sexually Transmitted Diseases (STD) Testing, by Country/Region, 2022–2031 (USD Million)
    Table 73    Global Prevalence Of HIV, by Region (2022)
    Table 74    Global In Vitro Diagnostics Market For HIV, by Country/Region, 2022–2031 (USD Million)
    Table 75    Global In Vitro Diagnostics Market for Healthcare Acquired Infections (HAIs), by Country/Region, 2022–2031 (USD Million)
    Table 76    Global In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2022–2031 (USD Million)
    Table 77    Global In Vitro Diagnostics Market For HIV, by Country/Region, 2022–2031 (USD Million)
    Table 78    Global In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2022–2031 (USD Million)
    Table 79    Global In Vitro Diagnostics Market for Influenza, by Country/Region, 2022–2031 (USD Million)
    Table 80    Global In Vitro Diagnostics Market for Respiratory Infections, by Country/Region, 2022–2031 (USD Million)
    Table 81    Global In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
    Table 82    Global In Vitro Diagnostics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
    Table 83    Number of People with Diabetes Aged 20–79 Years, by Region, 2021 Vs. 2030 Vs. 2045 (In Million)
    Table 84    Global In Vitro Diagnostics Market for Diabetes, by Country/Region, 2022–2031 (USD Million)
    Table 85    Global In Vitro Diagnostics Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
    Table 86    Global In Vitro Diagnostics Market for Nephrology, by Country/Region, 2022–2031 (USD Million)
    Table 87    Global In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2022–2031 (USD Million)
    Table 88    Global In Vitro Diagnostics Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
    Table 89    Global In Vitro Diagnostics Market, by Diagnostic Approach 2022–2031 (USD Million)
    Table 90    Global In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2022–2031 (USD Million)
    Table 91    Global In Vitro Diagnostics Market For OTC/Self-Testing, by Country/Region, 2022–2031 (USD Million)
    Table 92    Global In Vitro Diagnostics Market for Point-of-Care Testing, by Country/Region, 2022–2031 (USD Million)
    Table 93    Global In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 94    Global In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
    Table 95    Global In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
    Table 96    Global In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2022–2031 (USD Million)
    Table 97    Global In Vitro Diagnostics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
    Table 98    Global In Vitro Diagnostics Market, by Country/Region, 2022 Vs. 2031 (USD Million)
    Table 99    North America: In Vitro Diagnostics Market, by Country, 2022–2031 (USD Million)
    Table 100    North America: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 101    North America: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 102    North America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 103    North America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 104    North America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 105    North America: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 106    North America: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 107    North America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 108    North America: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 109    North America: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 110    U.S.: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 111    U.S.: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 112    U.S.: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 113    U.S.: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 114    U.S.: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 115    U.S.: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 116    U.S.: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 117    U.S.: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 118    U.S.: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 119    U.S.: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 120    Canada: Prevalence of Diseases/Conditions in The Geriatric (Age 65 Years and Above) Population (2019–2020)
    Table 121    Canada: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 122    Canada: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 123    Canada: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 124    Canada: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 125    Canada: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 126    Canada: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 127    Canada: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 128    Canada: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 129    Canada: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 130    Canada: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 131    Europe: In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 132    Europe: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 133    Europe: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 134    Europe: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 135    Europe: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 136    Europe: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 137    Europe: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 138    Europe: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 139    Europe: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 140    Europe: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 141    Europe: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 142    Germany: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 143    Germany: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 144    Germany: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 145    Germany: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 146    Germany: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 147    Germany: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 148    Germany: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 149    Germany: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 150    Germany: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 151    Germany: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 152    France: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 153    France: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 154    France: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 155    France: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 156    France: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 157    France: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 158    France: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 159    France: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 160    France: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 161    France: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 162    U.K.: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 163    U.K.: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 164    U.K.: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 165    U.K.: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 166    U.K.: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 167    U.K.: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 168    U.K.: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 169    U.K.: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 170    U.K.: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 171    U.K.: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 172    Italy: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 173    Italy: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 174    Italy: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 175    Italy: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 176    Italy: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 177    Italy: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 178    Italy: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 179    Italy: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 180    Italy: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 181    Italy: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 182    Spain: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 183    Spain: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 184    Spain: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 185    Spain: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 186    Spain: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 187    Spain: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 188    Spain: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 189    Spain: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 190    Spain: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 191    Spain: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 192    Switzerland: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 193    Switzerland: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 194    Switzerland: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 195    Switzerland: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 196    Switzerland: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 197    Switzerland: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 198    Switzerland: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 199    Switzerland: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 200    Switzerland: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 201    Switzerland: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 202    Rest of Europe: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 203    Rest of Europe: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 204    Rest of Europe: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 205    Rest of Europe: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 206    Rest of Europe: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 207    Rest of Europe: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 208    Rest of Europe: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 209    Rest of Europe: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 210    Rest of Europe: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 211    Rest of Europe: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 212    Asia-Pacific: In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 213    Asia-Pacific: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 214    Asia-Pacific: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 215    Asia-Pacific: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 216    Asia-Pacific: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 217    Asia-Pacific: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 218    Asia-Pacific: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 219    Asia-Pacific: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 220    Asia-Pacific: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 221    Asia-Pacific: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 222    Asia-Pacific: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 223    Japan: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 224    Japan: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 225    Japan: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 226    Japan: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 227    Japan: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 228    Japan: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 229    Japan: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 230    Japan: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 231    Japan: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 232    Japan: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 233    China: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 234    China: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 235    China: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 236    China: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 237    China: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 238    China: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 239    China: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 240    China: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 241    China: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 242    China: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 243    India: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 244    India: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 245    India: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 246    India: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 247    India: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 248    India: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 249    India: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 250    India: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 251    India: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 252    India: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 253    South Korea: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 254    South Korea: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 255    South Korea: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 256    South Korea: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 257    South Korea: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 258    South Korea: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 259    South Korea: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 260    South Korea: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 261    South Korea: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 262    South Korea: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 263    Australia: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 264    Australia: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 265    Australia: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 266    Australia: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 267    Australia: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 268    Australia: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 269    Australia: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 270    Australia: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 271    Australia: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 272    Australia: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 273    Rest of Asia-Pacific: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 274    Rest of Asia-Pacific: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 275    Rest of Asia-Pacific: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 276    Rest of Asia-Pacific: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 277    Rest of Asia-Pacific: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 278    Rest of Asia-Pacific: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 279    Rest of Asia-Pacific: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 280    Rest of Asia-Pacific: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 281    Rest of Asia-Pacific: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 282    Rest of Asia-Pacific: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 283    Latin America: In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 284    Latin America: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 285    Latin America: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 286    Latin America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 287    Latin America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 288    Latin America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 289    Latin America: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 290    Latin America: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 291    Latin America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 292    Latin America: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 293    Latin America: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 294    Testing Initiatives for COVID-19 In Brazil
    Table 295    Brazil: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 296    Brazil: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 297    Brazil: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 298    Brazil: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 299    Brazil: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 300    Brazil: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 301    Brazil: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 302    Brazil: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 303    Brazil: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 304    Brazil: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 305    Mexico: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 306    Mexico: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 307    Mexico: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 308    Mexico: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 309    Mexico: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 310    Mexico: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 311    Mexico: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 312    Mexico: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 313    Mexico: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 314    Mexico: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 315    Argentina: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 316    Argentina: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 317    Argentina: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 318    Argentina: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 319    Argentina: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 320    Argentina: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 321    Argentina: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 322    Argentina: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 323    Argentina: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 324    Argentina: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 325    Rest of Latin America: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 326    Rest of Latin America: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 327    Rest of Latin America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 328    Rest of Latin America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 329    Rest of Latin America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 330    Rest of Latin America: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 331    Rest of Latin America: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 332    Rest of Latin America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 333    Rest of Latin America: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 334    Rest of Latin America: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 335    Middle East: In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 336    Middle East: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 337    Middle East: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 338    Middle East: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 339    Middle East: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 340    Middle East: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 341    Middle East: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 342    Middle East: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 343    Middle East: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 344    Middle East: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 345    Middle East: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 346    Saudi Arabia: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 347    Saudi Arabia: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 348    Saudi Arabia: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 349    Saudi Arabia: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 350    Saudi Arabia: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 351    Saudi Arabia: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 352    Saudi Arabia: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 353    Saudi Arabia: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 354    Saudi Arabia: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 355    Saudi Arabia: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 356    Number of People Aged 65 Years and Above in The Middle East, 2017–2021 (In Thousands)
    Table 357    Rest of Middle East: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 358    Rest of Middle East: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 359    Rest of Middle East: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 360    Rest of Middle East: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 361    Rest of Middle East: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 362    Rest of Middle East: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 363    Rest of Middle East: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 364    Rest of Middle East: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 365    Rest of Middle East: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 366    Rest of Middle East: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 367    Africa: In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 368    Africa: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 369    Africa: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 370    Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 371    Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 372    Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 373    Africa: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 374    Africa: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 375    Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 376    Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 377    Africa: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 378    South Africa: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 379    South Africa: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 380    South Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 381    South Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 382    South Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 383    South Africa: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 384    South Africa: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 385    South Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 386    South Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 387    South Africa: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 388    Rest of Africa: In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
    Table 389    Rest of Africa: In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
    Table 390    Rest of Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
    Table 391    Rest of Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
    Table 392    Rest of Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
    Table 393    Rest of Africa: In Vitro Diagnostics Market for Point-of-Care (POC) Diagnostics, by Type, 2022–2031 (USD Million)
    Table 394    Rest of Africa: In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 395    Rest of Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
    Table 396    Rest of Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
    Table 397    Rest of Africa: In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 398    Recent Developments, by Company (2021–2024)

    List of Figure
    Figure 1    Research Process
    Figure 2    Secondary Sources Referenced for this Study
    Figure 3    Primary Research Techniques
    Figure 4    Key Executives Interviewed
    Figure 5    Breakdown of Primary Interviews (Supply-side & Demand-side)
    Figure 6    Market Size Estimation
    Figure 7    Global In Vitro Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
    Figure 8    Global In Vitro Diagnostics Market, by Technology, 2024 Vs. 2031 (USD Million)
    Figure 9    Global In Vitro Diagnostics Market, by Application, 2024 Vs. 2031 (USD Million)
    Figure 10    Global In Vitro Diagnostics Market, by Diagnostic Approach, 2024 Vs. 2031 (USD Million)
    Figure 11    Global In Vitro Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
    Figure 12    Global In Vitro Diagnostics Market, by Geography
    Figure 13    Impact Analysis of Market Dynamics
    Figure 14    U.S.: Medical and Health R&D Expenditure, 2018–2022 (USD Million)
    Figure 15    Global Biopharmaceutical R&D Expenditure, 2018–2028 (USD Billion)
    Figure 16    U.S. FDA Regulatory Pathways for IVD Kits
    Figure 17    EU Regulatory Pathway - IVDR 2017/746
    Figure 18    China: Medical Device Classification and Pre-Market Requirements for IVD Devices
    Figure 19    Vendor Selection Criteria
    Figure 20    Vendor/Brand Analysis
    Figure 20    Global In Vitro Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
    Figure 21    Global In Vitro Diagnostic Market, by Technology, 2024 Vs. 2031 (USD Million)
    Figure 22    Global In Vitro Diagnostics Market, by Application, 2024 Vs. 2031 (USD Million)
    Figure 23    U.S.: Estimated Acute Hepatitis C Cases, 2011–2020
    Figure 24    Estimated Number of New Cancer Cases, by Geography, 2020–2040 (Million)
    Figure 25    Total Number of Accredited Testing Laboratories (ISO/IEC 17025), 2016–2020
    Figure 26    Prevalence of Diabetes Across the World (In Million)
    Figure 27    Global In Vitro Diagnostics Market, by Diagnostic Approach 2024 Vs. 2031 (USD Million)
    Figure 28    Benefits of Laboratory Testing Approach
    Figure 29    Benefits of the Point-of-Care Testing Approach
    Figure 30    Global In Vitro Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
    Figure 31    Global In Vitro Diagnostics Market, by Region, 2024 Vs. 2031 (USD Million)
    Figure 32    North America: Number of People Aged 65 Years and Above, 2015–2021 (In Million)
    Figure 33    North America: Per Capita Health Expenditure (USD), 2017–2021
    Figure 34    Canada: Number of People Aged 65 And above, 2018–2022 (In Million)
    Figure 35    Europe: Number of People Aged 65 And Above, In Millions (2015–2021)
    Figure 36    Europe: In Vitro Diagnostics Market Snapshot
    Figure 37    France: Percentage of Population Aged 65 Years and Above (2016–2021)
    Figure 38    France: Prevalence of Chronic Diseases in People Aged 65 And Above (2020)
    Figure 39    U.K: Number of Cancer Cases, 2010–2030 (In Million)
    Figure 40    U.K.: Number of Diabetes and Urogenital, Blood, And Endocrine Disease Cases – DALYs (Disability-Adjusted Life Years), 2017–2020 (In Thousand)
    Figure 41    U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018–2020 (In Thousand)
    Figure 42    Italy: Ovarian Cancer Cases Diagnosed (2018–2020)
    Figure 43    Number of HIV Tests Performed in Catalonia (Spain) (2014–2021)
    Figure 44    Switzerland: Number of New Cancer Cases Reported (2020–2040)
    Figure 45    Switzerland: Number of People Aged 65 Years and Above (2017–2021)
    Figure 46    Asia-Pacific: In Vitro Diagnostics Market Snapshot
    Figure 47    Japan: Percentage Share of the Geriatric Population (Aged 65 Years and Above) (2015–2022)
    Figure 48    Japan: New Cancer Cases Reported (2020–2040)
    Figure 49    China: Independent Medical Laboratories Market, 2015–2021 (USD Million)
    Figure 50    India: Number of People Aged 65 Years and Above, 2017–2021 (Million)
    Figure 51    Latin America: In Vitro Diagnostics Market Snapshot
    Figure 52    Brazil: Challenges to The In Vitro Diagnostics Market
    Figure 53    Middle East: In Vitro Diagnostics Market Snapshot
    Figure 54    Saudi Arabia: Number of People Aged 65 Years and Above, 2017–2021 (In Thousand)
    Figure 55    Africa: In Vitro Diagnostics Market Snapshot
    Figure 56    South Africa: Number of People (All Ages) Living With HIV, 2010–2020 (In Million)
    Figure 57    South Africa: Number of People with Diabetes, 2000–2045 (In Thousand)
    Figure 58    Key Growth Strategies Adopted by Leading Players (2021–2024)
    Figure 59    Competitive Dashboard: Global In Vitro Diagnostics Market
    Figure 60    Global In Vitro Diagnostics Market Competitive Benchmarking, by Offering
    Figure 61    Competitive Dashboard In Vitro Diagnostics Market
    Figure 62    Market Share Analysis: Global In Vitro Diagnostics Market (2023)
    Figure 63    Abbott Laboratories: Financial Overview (2023)
    Figure 64    Becton, Dickinson and Company: Financial Overview (2023)
    Figure 65    bioMérieux SA: Financial Overview (2023)
    Figure 66    Danaher Corporation: Financial Overview (2023)
    Figure 67    F. Hoffman-La Roche Ltd: Financial Overview (2023)
    Figure 68    QIAGEN N.V.: Financial Overview (2023)
    Figure 69    Siemens Healthineers AG (A Subsidiary of Siemens Ag): Financial Overview (2023)
    Figure 70    Thermo Fisher Scientific Inc.: Financial Overview (2023)
    Figure 71    Bio-Rad Laboratories: Financial Overview (2023)
    Figure 72    Illumina, Inc.: Financial Overview (2023)
    Figure 73    Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2023)
    Figure 74    QuidelOrtho Corporation; Financial Overview (2023)
    Figure 75    Agilent Technologies, Inc.: Financial Overview (2023)
    Figure 76    DiaSorin S.p.A: Financial Overview (2023)
    Figure 77    Hologic, Inc.: Financial Overview (2023)

    Enquire
    Check Discount
    Author Name:

    Madhura Pawar, Pranjali Takale, Mahesh Khillari

    Related Tag: In-vitro Diagnostics Market IVD Market Disease Diagnostics Diagnostic Assays Diagnostic Kits Rapid Diagnostics Diagnostic Immunoassays Molecular Diagnostics
    In Vitro Diagnostics
    Healthcare
      This website is secure and we do not share your personal information with any third party. privacy policy
      You will also receive a PDF copy of this sample in your mailbox.

      Proudly Partnering With Enterprises Around the Globe

      Accenture Amazon BCG-Corporate BioRad Boehringer-Ingelheim Deloitte Fujifilm Intel PEPSICO Samsung Olympus McKinsey LG-Chem Rosetta-Stone tata-consultancy-services SK Kao IQVIA Vemag Canada Genscript Grupo-Vilaseca HEC Highland-Metals-Inc
      Related Tag: In-vitro Diagnostics Market IVD Market Disease Diagnostics Diagnostic Assays Diagnostic Kits Rapid Diagnostics Diagnostic Immunoassays Molecular Diagnostics
      Request Sample
      Customize My Report
      Quick Contact
      Chat on Whatsapp
      Linkdin
      Whatsapp
      Feed
      Related Reports
      IVD Reagents Market - Global Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: Jul-2024

      In Vitro Fertilization Market - Global Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: Jun-2024

      Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)

         Published Date: Feb-2024

      Middle East IVD Market - Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: Jan-2024

      Asia-Pacific IVD Market - Opportunity Analysis and Industry Forecasts (2024-2031)

         Published Date: Jan-2024

      Table Of Content
      Download Free Sample Report
      Meticulous Research
      US
      +1 646-781-8004
      Meticulous Research
      Europe
      +44-203-868-8738
      Meticulous Research
      APAC
      +91-744-778-0008